Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
The field is reaching a point where sleep health will become a top priority for public health as a result of the great strides made in the field over the past year, as well as the effects of the COVID-19 pandemic and lingering care challenges.
Read Full NewsA study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.
A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.
Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.
1.
Using AI, one can find cancer risk factors.
2.
New Gene Therapy Nears EU Nod for Bladder Cancer
3.
How breast tissue density affects your risk of breast cancer
4.
Young adults who are obese are at risk for 17 different types of cancer in the future.
5.
Distinct results for patients with positive and negative pancreatic cancer who are treated with systemic therapy, chemotherapy, and radiation.
1.
Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia
2.
CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma: A Comprehensive Review
3.
Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Evolution of Cancer Care Through Developmental Therapeutics
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
3.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge